These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. Hodis HN; Mack WJ; LaBree L; Cashin-Hemphill L; Sevanian A; Johnson R; Azen SP JAMA; 1995 Jun; 273(23):1849-54. PubMed ID: 7776501 [TBL] [Abstract][Full Text] [Related]
3. Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis. Implications for clinical trials. Waters D; Lespérance J; Craven TE; Hudon G; Gillam LD Circulation; 1993 Mar; 87(3 Suppl):II38-47. PubMed ID: 8443922 [TBL] [Abstract][Full Text] [Related]
4. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect. Blankenhorn DH; Selzer RH; Mack WJ; Crawford DW; Pogoda J; Lee PL; Shircore AM; Azen SP Circulation; 1992 Dec; 86(6):1701-9. PubMed ID: 1451241 [TBL] [Abstract][Full Text] [Related]
14. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet; 2001 Mar; 357(9260):905-10. PubMed ID: 11289345 [TBL] [Abstract][Full Text] [Related]
15. Measuring progression and regression of coronary atherosclerosis in clinical trials: problems and progress. Lespérance J; Waters D Int J Card Imaging; 1992; 8(3):165-73. PubMed ID: 1527439 [TBL] [Abstract][Full Text] [Related]
16. Regression of severe atherosclerotic plaque in patients with mild elevation of LDL cholesterol. Schaefer S; Hussein H; Gershony GR; Rutledge JC; Kappagoda CT J Investig Med; 1997 Dec; 45(9):536-41. PubMed ID: 9444880 [TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study. Nakagawa T; Kobayashi T; Awata N; Sato S; Reiber JH; Nakajima H; Toyama YN; Hiraoka H; Kato O; Kirino M; Kobayashi T; Takeda Y; Yachiku K; Iida M; Itoh T; Shibata N Int J Cardiol; 2004 Oct; 97(1):107-14. PubMed ID: 15336816 [TBL] [Abstract][Full Text] [Related]
18. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review. Frisinghelli A; Mafrici A Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568 [TBL] [Abstract][Full Text] [Related]
19. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. Post Coronary Artery Bypass Graft Trial Investigators N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351 [TBL] [Abstract][Full Text] [Related]